Specifically, in early-stage HR-negative/HER2-positive breast cancer, obese patients demonstrate a heightened risk of recurrence compared to those with a normal BMI (HR=2.29, 95% CI: 1.01-5.20, p=0.047) 51. This evidence concerns the gene ERBB2 and breast carcinoma.